Ocugen Inc ( (OCGN)) has released its Q3 earnings. Here is a breakdown of the information Ocugen Inc presented to its investors. Ocugen, Inc. is a biotechnology company specializing in the development ...
Rezolute, Inc. announced that enrollment for its Phase 3 sunRIZE study on congenital hyperinsulinism (HI) is on track to be completed by May 2025, with topline data expected in December 2025. The U.S.
Not only do many people make therapy a years-long process, but they may not be getting its full benefits. Here's how to be a good consumer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results